This database contains 5 studies, archived under the term: "replacement"
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials
Manson, JoAnn E.,
Chlebowski, Rowan T.,
Stefanick, Marcia L.,
Aragaki, Aaron K.,
Rossouw, Jacques E.,
Prentice, Ross L.,
Anderson, Garnet,
Howard, Barbara V.,
Thomson, Cynthia A.,
LaCroix, Andrea Z.,
Wactawski-Wende, Jean,
Jackson, Rebecca D.,
Limacher, Marian,
Margolis, Karen L.,
Wassertheil-Smoller, Sylvia,
Beresford, Shirley A.,
Cauley, Jane A.,
Eaton, Charles B.,
Gass, Margery,
Hsia, Judith,
Johnson, Karen C.,
Kooperberg, Charles,
Kuller, Lewis H.,
Lewis, Cora E.,
Liu, Simin,
Martin, Lisa W.,
Ockene, Judith K.,
O’Sullivan, Mary Jo,
Powell, Lynda H.,
Simon, Michael S.,
Van Horn, Linda,
Vitolins, Mara Z.,
Wallace, Robert B.
Importance: Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.; Objective: To report a comprehensive, integrated overview of findings from the 2 Women’s Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.; Design, Setting, and Participants: A total of 27,347 postmenopausal women aged 50 […]
Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use
Jacobs, Emily G.,
Kroenke, Candyce,
Lin, Jue,
Epel, Elissa S.,
Kenna, Heather A.,
Blackburn, Elizabeth H.,
Rasgon, Natalie L.
Apolipoprotein-ε4 (APOE-ε4) is a major genetic risk factor for cognitive decline, Alzheimer’s disease (AD) and early mortality. An accelerated rate of biological aging could contribute to this increased risk. Here, we determined whether APOE-ε4 status impacts leukocyte telomere length (TL) and the rate of cellular senescence in healthy mid-life women and, further, whether hormone replacement […]